JP4294217B2 - スチリルスルホン抗癌剤 - Google Patents
スチリルスルホン抗癌剤 Download PDFInfo
- Publication number
- JP4294217B2 JP4294217B2 JP2000514880A JP2000514880A JP4294217B2 JP 4294217 B2 JP4294217 B2 JP 4294217B2 JP 2000514880 A JP2000514880 A JP 2000514880A JP 2000514880 A JP2000514880 A JP 2000514880A JP 4294217 B2 JP4294217 B2 JP 4294217B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hydrogen
- mol
- fri
- fluorine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XJNHONCWGODPIZ-PHEQNACWSA-N [(e)-2-[(e)-2-phenylethenyl]sulfonylethenyl]benzene Chemical compound C=1C=CC=CC=1/C=C/S(=O)(=O)\C=C\C1=CC=CC=C1 XJNHONCWGODPIZ-PHEQNACWSA-N 0.000 title abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 28
- 239000001257 hydrogen Substances 0.000 claims abstract description 28
- 239000011737 fluorine Chemical group 0.000 claims abstract description 23
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 23
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 22
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000460 chlorine Chemical group 0.000 claims abstract description 21
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 21
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 15
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052794 bromium Chemical group 0.000 claims abstract description 15
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- URBLDUHDENNTET-MDZDMXLPSA-N 1-[[(e)-2-(4-bromophenyl)ethenyl]sulfonylmethyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(Br)C=C1 URBLDUHDENNTET-MDZDMXLPSA-N 0.000 claims description 4
- NXLVMMFSYHOBNA-BQYQJAHWSA-N 2,4-difluoro-1-[(e)-2-[(4-fluorophenyl)methylsulfonyl]ethenyl]benzene Chemical compound C1=CC(F)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(F)C=C1F NXLVMMFSYHOBNA-BQYQJAHWSA-N 0.000 claims description 4
- JJSHRTVHJFKOFB-MDZDMXLPSA-N 1-[[(e)-2-(4-bromophenyl)ethenyl]sulfonylmethyl]-4-chlorobenzene Chemical compound C1=CC(Cl)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(Br)C=C1 JJSHRTVHJFKOFB-MDZDMXLPSA-N 0.000 claims description 3
- ZDYHTOFOTBKCFQ-MDZDMXLPSA-N 1-bromo-4-[[(e)-2-(4-chlorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)CC1=CC=C(Br)C=C1 ZDYHTOFOTBKCFQ-MDZDMXLPSA-N 0.000 claims description 3
- CHQQDELDVCBHKN-MDZDMXLPSA-N 1-bromo-4-[[(e)-2-(4-fluorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(F)=CC=C1\C=C\S(=O)(=O)CC1=CC=C(Br)C=C1 CHQQDELDVCBHKN-MDZDMXLPSA-N 0.000 claims description 3
- QFXKVNVCBJMHBH-MDZDMXLPSA-N 1-fluoro-4-[[(e)-2-(4-fluorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(F)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(F)C=C1 QFXKVNVCBJMHBH-MDZDMXLPSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 94
- 210000004881 tumor cell Anatomy 0.000 abstract description 26
- -1 2-nitrophenyl Chemical group 0.000 abstract description 17
- 230000006907 apoptotic process Effects 0.000 abstract description 8
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 abstract description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 238000000034 method Methods 0.000 description 51
- 239000000243 solution Substances 0.000 description 39
- 230000000694 effects Effects 0.000 description 28
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 26
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 206010006187 Breast cancer Diseases 0.000 description 18
- 208000026310 Breast neoplasm Diseases 0.000 description 18
- 102000043136 MAP kinase family Human genes 0.000 description 17
- 108091054455 MAP kinase family Proteins 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 208000023958 prostate neoplasm Diseases 0.000 description 15
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 14
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 12
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 11
- 239000003098 androgen Substances 0.000 description 11
- 210000000481 breast Anatomy 0.000 description 10
- 150000002170 ethers Chemical class 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000013592 cell lysate Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000007717 exclusion Effects 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- WCOXFTGMNJJABC-SREVYHEPSA-N 2-[(z)-2-phenylethenyl]sulfonylacetic acid Chemical compound OC(=O)CS(=O)(=O)\C=C/C1=CC=CC=C1 WCOXFTGMNJJABC-SREVYHEPSA-N 0.000 description 7
- HPWAJMXOEYIERK-UHFFFAOYSA-N 2-benzylsulfonylacetic acid Chemical class OC(=O)CS(=O)(=O)CC1=CC=CC=C1 HPWAJMXOEYIERK-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 150000003934 aromatic aldehydes Chemical class 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 102000015694 estrogen receptors Human genes 0.000 description 7
- 108010038795 estrogen receptors Proteins 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 6
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 6
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 102000047918 Myelin Basic Human genes 0.000 description 6
- 101710107068 Myelin basic protein Proteins 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 239000012047 saturated solution Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- XJNHONCWGODPIZ-AOGCGKDYSA-N 2-[(e)-2-phenylethenyl]sulfonylethenylbenzene Chemical class C=1C=CC=CC=1/C=C/S(=O)(=O)C=CC1=CC=CC=C1 XJNHONCWGODPIZ-AOGCGKDYSA-N 0.000 description 5
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WXVZZCHUAIGQKJ-MDZDMXLPSA-N 1-chloro-4-[[(e)-2-(4-chlorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(Cl)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(Cl)C=C1 WXVZZCHUAIGQKJ-MDZDMXLPSA-N 0.000 description 4
- IAONCYGNBVHNCT-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfonylacetic acid Chemical compound OC(=O)CS(=O)(=O)C1=CC=C(Cl)C=C1 IAONCYGNBVHNCT-UHFFFAOYSA-N 0.000 description 4
- YTEFAALYDTWTLB-UHFFFAOYSA-N 2-(benzenesulfonyl)acetic acid Chemical compound OC(=O)CS(=O)(=O)C1=CC=CC=C1 YTEFAALYDTWTLB-UHFFFAOYSA-N 0.000 description 4
- 101100397594 Ancylostoma caninum JNK-1 gene Proteins 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000010337 G2 phase Effects 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- GMKXPTFOBQFAOD-MDZDMXLPSA-N 1-chloro-4-[[(e)-2-(4-fluorophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(F)=CC=C1\C=C\S(=O)(=O)CC1=CC=C(Cl)C=C1 GMKXPTFOBQFAOD-MDZDMXLPSA-N 0.000 description 3
- VMYFZBLZKJJKLR-UHFFFAOYSA-N 2-[(4-bromophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(Br)C=C1 VMYFZBLZKJJKLR-UHFFFAOYSA-N 0.000 description 3
- YYXBXAYHHCTPEF-UHFFFAOYSA-N 2-[(4-chlorophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(Cl)C=C1 YYXBXAYHHCTPEF-UHFFFAOYSA-N 0.000 description 3
- STQLDAZMDJUSKV-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(F)C=C1 STQLDAZMDJUSKV-UHFFFAOYSA-N 0.000 description 3
- XJNHONCWGODPIZ-CSXFVWEESA-N 2-[(Z)-2-phenylethenyl]sulfonylethenylbenzene Chemical class C(=C/C1=CC=CC=C1)/S(=O)(=O)C=CC1=CC=CC=C1 XJNHONCWGODPIZ-CSXFVWEESA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- XMBPHCAGUFSFOJ-UHFFFAOYSA-N 3-oxo-4-sulfonylbutanoic acid Chemical class S(=O)(=O)=CC(CC(=O)O)=O XMBPHCAGUFSFOJ-UHFFFAOYSA-N 0.000 description 3
- SEUYMUDVXBSSGT-UHFFFAOYSA-N 4-phenylbut-3-enethioic s-acid Chemical compound SC(=O)CC=CC1=CC=CC=C1 SEUYMUDVXBSSGT-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- MRTIWTGAGMZREP-QXMHVHEDSA-N [(z)-2-phenylethenyl]sulfonylmethylbenzene Chemical class C=1C=CC=CC=1\C=C/S(=O)(=O)CC1=CC=CC=C1 MRTIWTGAGMZREP-QXMHVHEDSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- AWHNUHMUCGRKRA-UHFFFAOYSA-N benzylsulfonylmethylbenzene Chemical class C=1C=CC=CC=1CS(=O)(=O)CC1=CC=CC=C1 AWHNUHMUCGRKRA-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940106681 chloroacetic acid Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000000865 phosphorylative effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000005267 prostate cell Anatomy 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- VYKVQJFOZDGJLN-UHFFFAOYSA-M sodium hydrogen sulfite sulfurous acid Chemical compound [Na+].OS(O)=O.OS([O-])=O VYKVQJFOZDGJLN-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 230000004565 tumor cell growth Effects 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- SYTHOKWALOYRAP-UHFFFAOYSA-N 2-[2-chloro-3-(2-chloro-3-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C1=CC=C(S(=O)(=O)C=2C(=C(CC(=O)C=3C=CC=CC=3)C=CC=2)Cl)C(Cl)=C1CC(=O)C1=CC=CC=C1 SYTHOKWALOYRAP-UHFFFAOYSA-N 0.000 description 2
- JXHLDZVRNMLMEB-UHFFFAOYSA-N 2-[5-fluoro-2-(4-fluoro-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C(F)=CC=C(S(=O)(=O)C=2C(=CC(F)=CC=2)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 JXHLDZVRNMLMEB-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 2
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- MRTIWTGAGMZREP-VAWYXSNFSA-N [(e)-2-phenylethenyl]sulfonylmethylbenzene Chemical class C=1C=CC=CC=1/C=C/S(=O)(=O)CC1=CC=CC=C1 MRTIWTGAGMZREP-VAWYXSNFSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- GMZMXCZTVDOYNX-ZHACJKMWSA-N 1-[(e)-2-(4-chlorophenyl)sulfonylethenyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1\C=C\S(=O)(=O)C1=CC=C(Cl)C=C1 GMZMXCZTVDOYNX-ZHACJKMWSA-N 0.000 description 1
- LUFVQVKHWIYXIB-ZHACJKMWSA-N 1-[(e)-2-(4-chlorophenyl)sulfonylethenyl]-4-methylbenzene Chemical compound C1=CC(C)=CC=C1\C=C\S(=O)(=O)C1=CC=C(Cl)C=C1 LUFVQVKHWIYXIB-ZHACJKMWSA-N 0.000 description 1
- QPMFUCLWWAQPBD-CMDGGOBGSA-N 1-[(e)-2-(benzenesulfonyl)ethenyl]-2,4-dichlorobenzene Chemical compound ClC1=CC(Cl)=CC=C1\C=C\S(=O)(=O)C1=CC=CC=C1 QPMFUCLWWAQPBD-CMDGGOBGSA-N 0.000 description 1
- RPDRBEJDYHVLME-ZHACJKMWSA-N 1-[(e)-2-(benzenesulfonyl)ethenyl]-4-bromobenzene Chemical compound C1=CC(Br)=CC=C1\C=C\S(=O)(=O)C1=CC=CC=C1 RPDRBEJDYHVLME-ZHACJKMWSA-N 0.000 description 1
- FXYBLJJXHQXMTH-ZHACJKMWSA-N 1-[(e)-2-(benzenesulfonyl)ethenyl]-4-chlorobenzene Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)C1=CC=CC=C1 FXYBLJJXHQXMTH-ZHACJKMWSA-N 0.000 description 1
- YMRHRTUPMUIKBX-ZHACJKMWSA-N 1-[(e)-2-benzylsulfonylethenyl]-2-chlorobenzene Chemical compound ClC1=CC=CC=C1\C=C\S(=O)(=O)CC1=CC=CC=C1 YMRHRTUPMUIKBX-ZHACJKMWSA-N 0.000 description 1
- CQQMYELYPHEXMW-ZHACJKMWSA-N 1-[(e)-2-benzylsulfonylethenyl]-4-chlorobenzene Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)CC1=CC=CC=C1 CQQMYELYPHEXMW-ZHACJKMWSA-N 0.000 description 1
- HVSMMGMOGXMVNZ-MDZDMXLPSA-N 1-bromo-4-[(e)-2-(4-chlorophenyl)sulfonylethenyl]benzene Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)\C=C\C1=CC=C(Br)C=C1 HVSMMGMOGXMVNZ-MDZDMXLPSA-N 0.000 description 1
- BPCWSTIDUJXABN-MDZDMXLPSA-N 1-bromo-4-[[(e)-2-(4-bromophenyl)ethenyl]sulfonylmethyl]benzene Chemical compound C1=CC(Br)=CC=C1CS(=O)(=O)\C=C\C1=CC=C(Br)C=C1 BPCWSTIDUJXABN-MDZDMXLPSA-N 0.000 description 1
- BHZSVOGMDVLRRR-MDZDMXLPSA-N 1-chloro-4-[(e)-2-(4-chlorophenyl)sulfonylethenyl]benzene Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)C1=CC=C(Cl)C=C1 BHZSVOGMDVLRRR-MDZDMXLPSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- YSFBEAASFUWWHU-UHFFFAOYSA-N 2,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C(Cl)=C1 YSFBEAASFUWWHU-UHFFFAOYSA-N 0.000 description 1
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 1
- RAFWRUNTUFYFAC-UHFFFAOYSA-N 2-(2-chlorophenyl)sulfonyl-3-(4-fluorophenyl)-1-phenylprop-2-en-1-one Chemical compound C1=CC(F)=CC=C1C=C(S(=O)(=O)C=1C(=CC=CC=1)Cl)C(=O)C1=CC=CC=C1 RAFWRUNTUFYFAC-UHFFFAOYSA-N 0.000 description 1
- WCOXFTGMNJJABC-UHFFFAOYSA-N 2-(2-phenylethenylsulfonyl)acetic acid Chemical compound OC(=O)CS(=O)(=O)C=CC1=CC=CC=C1 WCOXFTGMNJJABC-UHFFFAOYSA-N 0.000 description 1
- DREVPGKOIZVPQV-UHFFFAOYSA-N 2-(benzenesulfonyl)-1-phenylethanone Chemical compound C=1C=CC=CC=1C(=O)CS(=O)(=O)C1=CC=CC=C1 DREVPGKOIZVPQV-UHFFFAOYSA-N 0.000 description 1
- RIUCTGMEDZCYKZ-UHFFFAOYSA-N 2-[2-nitro-3-(2-nitro-3-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C1=CC=C(S(=O)(=O)C=2C(=C(CC(=O)C=3C=CC=CC=3)C=CC=2)[N+]([O-])=O)C([N+](=O)[O-])=C1CC(=O)C1=CC=CC=C1 RIUCTGMEDZCYKZ-UHFFFAOYSA-N 0.000 description 1
- DSNUPUMBSSCFHS-UHFFFAOYSA-N 2-[5-bromo-2-(4-bromo-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C(Br)=CC=C(S(=O)(=O)C=2C(=CC(Br)=CC=2)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 DSNUPUMBSSCFHS-UHFFFAOYSA-N 0.000 description 1
- WXBWJTDIRGOOAN-UHFFFAOYSA-N 2-[5-chloro-2-(4-chloro-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C(Cl)=CC=C(S(=O)(=O)C=2C(=CC(Cl)=CC=2)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 WXBWJTDIRGOOAN-UHFFFAOYSA-N 0.000 description 1
- AMJUCPMWRHEFEO-UHFFFAOYSA-N 2-[5-methoxy-2-(4-methoxy-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C(OC)=CC=C(S(=O)(=O)C=2C(=CC(OC)=CC=2)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 AMJUCPMWRHEFEO-UHFFFAOYSA-N 0.000 description 1
- YPAMEUJNJVCLNP-UHFFFAOYSA-N 2-[5-nitro-2-(4-nitro-2-phenacylphenyl)sulfonylphenyl]-1-phenylethanone Chemical compound C=1C([N+](=O)[O-])=CC=C(S(=O)(=O)C=2C(=CC(=CC=2)[N+]([O-])=O)CC(=O)C=2C=CC=CC=2)C=1CC(=O)C1=CC=CC=C1 YPAMEUJNJVCLNP-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- VYNUATGQEAAPAQ-UHFFFAOYSA-N 2-sulfonylacetic acid Chemical compound OC(=O)C=S(=O)=O VYNUATGQEAAPAQ-UHFFFAOYSA-N 0.000 description 1
- KWVKOYBKUXUKDS-UHFFFAOYSA-N 3-(4-bromophenyl)-2-(2-chlorophenyl)sulfonyl-1-phenylprop-2-en-1-one Chemical compound ClC1=CC=CC=C1S(=O)(=O)C(C(=O)C=1C=CC=CC=1)=CC1=CC=C(Br)C=C1 KWVKOYBKUXUKDS-UHFFFAOYSA-N 0.000 description 1
- QAWBXYVZQVGZAP-UHFFFAOYSA-N 3-(4-bromophenyl)-2-(2-nitrophenyl)sulfonyl-1-phenylprop-2-en-1-one Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)C(C(=O)C=1C=CC=CC=1)=CC1=CC=C(Br)C=C1 QAWBXYVZQVGZAP-UHFFFAOYSA-N 0.000 description 1
- NKEZKRHTIDOVSX-UHFFFAOYSA-N 3-(4-bromophenyl)-2-(4-chlorophenyl)sulfonyl-1-phenylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC=CC=1)=CC1=CC=C(Br)C=C1 NKEZKRHTIDOVSX-UHFFFAOYSA-N 0.000 description 1
- HKSMWZCEBDDOSD-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-(4-fluorophenyl)sulfonyl-1-phenylprop-2-en-1-one Chemical compound C1=CC(F)=CC=C1C=C(S(=O)(=O)C=1C=CC(F)=CC=1)C(=O)C1=CC=CC=C1 HKSMWZCEBDDOSD-UHFFFAOYSA-N 0.000 description 1
- JZLMLFCJWFMZMC-UHFFFAOYSA-N 3-phenylpropanethioic s-acid Chemical class SC(=O)CCC1=CC=CC=C1 JZLMLFCJWFMZMC-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ATQYXMMYXOTCDA-JQBMIRIKSA-N C1=CC(Br)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(Br)=CC=1)/C=C\C1=CC=CC=C1 Chemical compound C1=CC(Br)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(Br)=CC=1)/C=C\C1=CC=CC=C1 ATQYXMMYXOTCDA-JQBMIRIKSA-N 0.000 description 1
- RXIAYSLAWGTXBE-JQBMIRIKSA-N C1=CC(Cl)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(Cl)=CC=1)/C=C\C1=CC=CC=C1 Chemical compound C1=CC(Cl)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(Cl)=CC=1)/C=C\C1=CC=CC=C1 RXIAYSLAWGTXBE-JQBMIRIKSA-N 0.000 description 1
- YHCMQPPHPAYPQM-JQBMIRIKSA-N C1=CC(F)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(F)=CC=1)/C=C\C1=CC=CC=C1 Chemical compound C1=CC(F)=CC=C1\C=C(\S(=O)(=O)\C(\C=C/C=1C=CC=CC=1)=C\C=1C=CC(F)=CC=1)/C=C\C1=CC=CC=C1 YHCMQPPHPAYPQM-JQBMIRIKSA-N 0.000 description 1
- XJNHONCWGODPIZ-XSYHWHKQSA-N C=1C=CC=CC=1\C=C/S(=O)(=O)\C=C/C1=CC=CC=C1 Chemical class C=1C=CC=CC=1\C=C/S(=O)(=O)\C=C/C1=CC=CC=C1 XJNHONCWGODPIZ-XSYHWHKQSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 108030004793 Dual-specificity kinases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 1
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- DNMCCXFLTURVLK-VAWYXSNFSA-N [(e)-2-(benzenesulfonyl)ethenyl]benzene Chemical compound C=1C=CC=CC=1S(=O)(=O)\C=C\C1=CC=CC=C1 DNMCCXFLTURVLK-VAWYXSNFSA-N 0.000 description 1
- WZDKIPVHBCBPCR-QXMHVHEDSA-N [(z)-2-benzylsulfanylethenyl]benzene Chemical class C=1C=CC=CC=1CS\C=C/C1=CC=CC=C1 WZDKIPVHBCBPCR-QXMHVHEDSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940079826 hydrogen sulfite Drugs 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- QXLPXWSKPNOQLE-UHFFFAOYSA-N methylpentynol Chemical compound CCC(C)(O)C#C QXLPXWSKPNOQLE-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical class BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/12—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Graft Or Block Polymers (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6093397P | 1997-10-03 | 1997-10-03 | |
| US60/060,933 | 1997-10-03 | ||
| PCT/US1998/020580 WO1999018068A1 (en) | 1997-10-03 | 1998-10-01 | Styryl sulfone anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001519326A JP2001519326A (ja) | 2001-10-23 |
| JP2001519326A5 JP2001519326A5 (enExample) | 2006-02-09 |
| JP4294217B2 true JP4294217B2 (ja) | 2009-07-08 |
Family
ID=22032642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000514880A Expired - Fee Related JP4294217B2 (ja) | 1997-10-03 | 1998-10-01 | スチリルスルホン抗癌剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6359013B1 (enExample) |
| EP (1) | EP1027330B1 (enExample) |
| JP (1) | JP4294217B2 (enExample) |
| KR (1) | KR100579355B1 (enExample) |
| CN (1) | CN1163480C (enExample) |
| AT (1) | ATE284386T1 (enExample) |
| AU (1) | AU741042B2 (enExample) |
| BR (1) | BR9814059B1 (enExample) |
| CA (1) | CA2305790C (enExample) |
| CZ (1) | CZ299718B6 (enExample) |
| DE (1) | DE69828079T2 (enExample) |
| IL (1) | IL135438A (enExample) |
| NZ (1) | NZ503479A (enExample) |
| RU (1) | RU2201919C2 (enExample) |
| WO (1) | WO1999018068A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548553B2 (en) | 1997-10-03 | 2003-04-15 | Temple University-Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| US6762207B1 (en) * | 1999-04-02 | 2004-07-13 | Temple University - Of The Commonwealth System Of Higher Education | (E)-styryl sulfone anticancer agents |
| CA2366750C (en) * | 1999-04-02 | 2010-06-01 | Temple University - Of The Commonwealth System Of Higher Education | (e)-styryl sulfone anticancer agents |
| AU778825B2 (en) | 1999-06-16 | 2004-12-23 | Temple University - Of The Commonwealth System Of Higher Education | (Z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors |
| CA2387539C (en) * | 1999-10-12 | 2010-09-21 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| US6767926B1 (en) * | 1999-10-12 | 2004-07-27 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| US6541475B2 (en) * | 2000-04-14 | 2003-04-01 | Temple University - Of The Commonwealth System Of Higher Education | α, β-unsaturated sulfones for treating proliferative disorders |
| US6486210B2 (en) | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
| CA2424884C (en) * | 2000-10-05 | 2009-12-15 | E. Premkumar Reddy | Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| WO2002067913A1 (en) * | 2001-02-27 | 2002-09-06 | Temple University-Of The Commonwealth System Of Higher Education | (z)-styrylbenzylsulfones and pharmaceutical uses thereof |
| JP4302986B2 (ja) * | 2001-02-28 | 2009-07-29 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法 |
| IL163608A0 (en) * | 2002-02-28 | 2005-12-18 | Univ Temple | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| US7598232B2 (en) * | 2002-02-28 | 2009-10-06 | Temple University - Of The Commonwealth System Of Higher Education | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| DK1689706T3 (da) * | 2003-11-14 | 2017-04-03 | Temple Univ - Of The Commonwealth System Of Higher Education | Alfa, beta-umættede sulfoxider til behandling af proliferative forstyrrelser |
| US7932242B2 (en) | 2004-03-16 | 2011-04-26 | Temple University - Of The Commonwealth System Of Higher Education | Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders |
| ATE529106T1 (de) | 2004-06-24 | 2011-11-15 | Univ Temple | Alpha-, beta-ungesättigte sulfone, sulfonoxide, sulfonimide, sulfinimide, acylsulfonamide und acylsulfinamide und therapeutische verwendungen damit |
| AU2006204103B2 (en) * | 2005-01-05 | 2011-11-24 | Temple University Of The Commonwealth System Of Higher Education | Treatment of drug-resistant proliferative disorders |
| EP1896401B1 (en) * | 2005-02-25 | 2013-04-10 | Temple University - Of The Commonwealth System of Higher Education | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis |
| US8664272B2 (en) | 2006-08-30 | 2014-03-04 | Temple University—Of the Commonwealth System of Higher Education | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| WO2008033475A2 (en) * | 2006-09-15 | 2008-03-20 | Onconova Therapeutics, Inc. | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions |
| WO2008076270A2 (en) * | 2006-12-13 | 2008-06-26 | Temple University-Of The Commonwealth System Of Higher Education | Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof |
| WO2014047110A2 (en) | 2012-09-20 | 2014-03-27 | Temple University - Of The Commonwealth System Of Higher Education | Substituted alkyl diaryl derivatives, methods of preparation and uses |
| WO2014089483A1 (en) | 2012-12-07 | 2014-06-12 | Onconova Therapeutics, Inc. | Methods and compositions for treatment of cancer |
| WO2017023912A1 (en) | 2015-08-03 | 2017-02-09 | Temple University - Of The Commonwealth System Of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2532612A (en) | 1945-08-29 | 1950-12-05 | Union Oil Co | Preparation of unsaturated thio-ethers |
| US3185743A (en) | 1960-08-24 | 1965-05-25 | Union Carbide Corp | Production of olefinic compounds from allyl sulfones |
| US3418101A (en) | 1965-12-15 | 1968-12-24 | Pennsalt Chemicals Corp | Process for plant desiccation |
| US3514386A (en) | 1967-12-11 | 1970-05-26 | Exxon Research Engineering Co | Stereoselective addition of thiols to acetylenic compounds |
| US3917714A (en) | 1972-09-06 | 1975-11-04 | American Cyanamid Co | Bis(alkylsulfonyl)vinylbenzenes |
| US4161407A (en) | 1977-10-06 | 1979-07-17 | Eastman Kodak Company | Crosslinkable polymers having vinylsulfonyl groups or styrylsulfonyl groups and their use as hardeners for gelatin |
| US4386221A (en) | 1981-10-28 | 1983-05-31 | Eastman Kodak Company | Process for the preparation of aryl alkyl sulfones and aryl vinyl sulfones |
| US4937388A (en) | 1985-08-09 | 1990-06-26 | Imperial Chemical Industries Plc | Insecticidal ethers |
| FR2645536B1 (fr) * | 1989-04-10 | 1991-05-31 | Rhone Poulenc Agrochimie | Composes herbicides et les compositions les contenant |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| AU6112896A (en) * | 1995-06-07 | 1996-12-30 | Sugen, Inc. | Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders |
| US5659087A (en) | 1995-06-07 | 1997-08-19 | Eli Lilly And Company | Diarylvinyl sulfoxides |
-
1998
- 1998-10-01 US US09/509,227 patent/US6359013B1/en not_active Expired - Lifetime
- 1998-10-01 JP JP2000514880A patent/JP4294217B2/ja not_active Expired - Fee Related
- 1998-10-01 CZ CZ20001174A patent/CZ299718B6/cs not_active IP Right Cessation
- 1998-10-01 BR BRPI9814059-0A patent/BR9814059B1/pt not_active IP Right Cessation
- 1998-10-01 EP EP98949680A patent/EP1027330B1/en not_active Expired - Lifetime
- 1998-10-01 AT AT98949680T patent/ATE284386T1/de not_active IP Right Cessation
- 1998-10-01 AU AU95954/98A patent/AU741042B2/en not_active Ceased
- 1998-10-01 CA CA002305790A patent/CA2305790C/en not_active Expired - Fee Related
- 1998-10-01 IL IL13543898A patent/IL135438A/xx not_active IP Right Cessation
- 1998-10-01 RU RU2000111513/04A patent/RU2201919C2/ru not_active IP Right Cessation
- 1998-10-01 CN CNB988098199A patent/CN1163480C/zh not_active Expired - Fee Related
- 1998-10-01 NZ NZ503479A patent/NZ503479A/xx not_active IP Right Cessation
- 1998-10-01 KR KR1020007003554A patent/KR100579355B1/ko not_active Expired - Fee Related
- 1998-10-01 DE DE69828079T patent/DE69828079T2/de not_active Expired - Lifetime
- 1998-10-01 WO PCT/US1998/020580 patent/WO1999018068A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20001174A3 (cs) | 2000-09-13 |
| ATE284386T1 (de) | 2004-12-15 |
| RU2201919C2 (ru) | 2003-04-10 |
| AU9595498A (en) | 1999-04-27 |
| DE69828079T2 (de) | 2005-12-22 |
| BR9814059B1 (pt) | 2010-08-24 |
| NZ503479A (en) | 2002-08-28 |
| JP2001519326A (ja) | 2001-10-23 |
| KR100579355B1 (ko) | 2006-05-12 |
| WO1999018068A1 (en) | 1999-04-15 |
| IL135438A (en) | 2005-12-18 |
| KR20010015689A (ko) | 2001-02-26 |
| CN1273580A (zh) | 2000-11-15 |
| AU741042B2 (en) | 2001-11-22 |
| EP1027330A4 (en) | 2003-09-10 |
| EP1027330A1 (en) | 2000-08-16 |
| EP1027330B1 (en) | 2004-12-08 |
| CA2305790C (en) | 2008-09-23 |
| CN1163480C (zh) | 2004-08-25 |
| HK1031373A1 (en) | 2001-06-15 |
| CA2305790A1 (en) | 1999-04-15 |
| IL135438A0 (en) | 2001-05-20 |
| US6359013B1 (en) | 2002-03-19 |
| BR9814059A (pt) | 2000-09-26 |
| DE69828079D1 (de) | 2005-01-13 |
| CZ299718B6 (cs) | 2008-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4294217B2 (ja) | スチリルスルホン抗癌剤 | |
| US6548553B2 (en) | Styryl sulfone anticancer agents | |
| JP4468593B2 (ja) | Ｚ−スチリルスルホン抗癌剤 | |
| US6642410B2 (en) | Substituted benzylthioacetic acids and esters | |
| US7056953B2 (en) | (E)-styryl sulfone anticancer agents | |
| EP1173160B1 (en) | (e)-styryl sulfone anticancer agents | |
| JP2002541101A (ja) | スチリルスルホン抗癌剤 | |
| HK1031373B (en) | Styryl sulfone anticancer agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20050928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050930 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050930 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081110 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090212 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090324 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090408 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120417 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120417 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130417 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130417 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140417 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |